乌司他丁与奥曲肽治疗重症急性胰腺炎的效果

Effect of Ulinastatin and Octreotide in the Treatment of Severe Acute Pancreatitis

目的:探究在重症急性胰腺炎患者中联合使用乌司他丁与奥曲肽的临床效果。方法:选取2021年3月-2022年3月于福建医科大学附属龙岩第一医院就诊的64例重症急性胰腺炎患者作为观察对象,按随机数表法将其分为对照组和研究组,各32例。对照组应用奥曲肽治疗,研究组应用奥曲肽与乌司他丁治疗。比较两组治疗前后免疫功能(免疫球蛋白A、免疫球蛋白M、免疫球蛋白G)、血管内皮素(ET)、细胞间黏附分子-1(ICAM-1)、血小板活化因子(PAF)、胞外热休克蛋白(HSP70)水平;统计两组不良反应发生情况。结果:治疗后,两组免疫球蛋白A、免疫球蛋白M、免疫球蛋白G水平均高于治疗前,研究组免疫球蛋白G水平高于对照组,差异有统计学意义(P<0.05),两组免疫球蛋白A、免疫球蛋白M比较,差异无统计学意义(P>0.05)。治疗后,两组ICAM-1、PAF、ET、HSP70水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。研究组不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论:重症急性胰腺炎患者联合使用乌司他丁与奥曲肽治疗,能够有效改善患者免疫功能,降低ICAM-1、PAF、ET、HSP70水平,不良反应发生率低。

Objective:To explore the clinical effect of Ulinastatin combined with Octreotide in patients with severe acute pancreatitis.Method:A total of 64 patients with severe acute pancreatitis who visited Longyan First Hospital Affiliated to Fujian Medical University from March 2021 to March 2022 were selected as the observation objects,and they were divided into the control group and the study group according to the random number table method,with 32 cases in each group.The control group was treated with Octreotide,and the study group was treated with Octreotide and Ulinastatin.The levels of immune function(immunoglobulin A,immunoglobulin M,immunoglobulin G),endothelin(ET),intercellular adhesion molecule-1(ICAM-1),platelet activating factor(PAF)and extracellular heat shock protein(HSP70)before and after treatment were compared between the two groups,the occurrence of adverse reactions in the two groups was analyzed.Result:After treatment,the levels of immunoglobulin A,immunoglobulin M and immunoglobulin G in both groups were higher than those before treatment,the level of immunoglobulin G in the study group was higher than that in the control group,the differences were statistically significant(P<0.05),but there were no statistically significant differences in immunoglobulin A and immunoglobulin M between the two groups(P>0.05).After treatment,the levels of ICAM-1,PAF,ET and HSP70 in both groups were lower than those before treatment,and the study group were lower than those of the control group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the study group was lower than that in the control group,the difference was statistically significant(P<0.05).Conclusion:In patients with severe acute pancreatitis,Ulinastatin combined with Octreotide can effectively improve the immune function of patients,reduce the levels of ICAM-1,PAF,ET and HSP70,and the incidence of adverse reactions is low.